New brain scan could sharpen radiation aim for deadliest tumors

NCT ID NCT06451042

Completed Diagnosis Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special type of PET/MRI scan using a radioactive tracer called FET can better map glioblastoma brain tumors after surgery compared to standard MRI. The goal was to see if this could help doctors plan radiation therapy more accurately. Eleven adults who had surgery for glioblastoma were scanned with both methods, and researchers compared the radiation treatment volumes. The study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FET (0-(2-18F-Fluoroethyl)-L-Tyrosine) radioactive tracer
What this could lead to: If successful, this imaging method could help doctors target radiation more precisely, potentially improving survival and reducing side effects for glioblastoma patients.
What could go wrong: This was a very small study (11 people) and only measured differences in treatment volume, not actual patient outcomes. The approach may not improve survival or quality of life in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.